This company has been acquired
Semler Scientific Zukünftiges Wachstum
Future Kriterienprüfungen 0/6
Der Umsatz und der Gewinn von Semler Scientific werden voraussichtlich um 5.7% bzw. 187.8% pro Jahr zurückgehen, während der Gewinn je Aktie voraussichtlich um 195.4% pro Jahr sinken wird.
Wichtige Informationen
-187.8%
Wachstumsrate der Gewinne
-195.44%
EPS-Wachstumsrate
| Medical Equipment Gewinnwachstum | 16.1% |
| Wachstumsrate der Einnahmen | -5.7% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 16 Jan 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
SMLR: All Stock Strive Deal Will Unlock Bitcoin Treasury Upside
Analysts have reaffirmed their fair value estimate for Semler Scientific at US$86.00, highlighting adjusted assumptions around the discount rate, revenue trends and profit margin, along with a lower but still very large future P/E expectation as the key drivers behind holding the target steady. What's in the News Strive, Inc.
SMLR: Future Profits And January Meeting Will Support Bullish Thesis
Analysts have reduced their price target on Semler Scientific from US$60.00 to US$51.00, citing softer revenue growth assumptions, a higher discount rate, and a very large future P/E multiple, even as projected profit margins edge slightly higher. What's in the News Semler Scientific has scheduled a special or extraordinary shareholders meeting for January 13, 2026, giving investors a date to watch for company level decisions or approvals that require shareholder input (Key Developments).SMLR: All Stock Acquisition Will Unlock Bitcoin Treasury Upside
Analysts have reduced their price target on Semler Scientific to $86 from $101, citing lower revenue and margin forecasts, as well as uncertainty and opportunity created by the recent all stock acquisition agreement and legal settlement. Analyst Commentary Bullish analysts acknowledge the reduced price targets but continue to frame the all stock acquisition and legal settlement as catalysts that could unlock value for Semler Scientific over the medium term.
SMLR: Shares Will Rise As All Stock Acquisition Drives Bitcoin Treasury Consolidation
Analysts have trimmed their average price target for Semler Scientific by about $15 to roughly $83 per share, citing reduced revenue expectations following updated management guidance and the implications of the recent DOJ settlement. They continue to view the stock as an attractive opportunity in light of the pending all stock acquisition by Strive and consolidation prospects in the corporate bitcoin treasury space.SMLR: Shares Will Reflect Upside As $1.4 Billion Acquisition Advances
Analysts have lowered their fair value estimate for Semler Scientific by approximately $10. This change is due to reduced revenue growth projections and updated guidance in light of recent acquisition and settlement developments.Cardiac And Digital Health Expansion Will Encounter Bitcoin Risks
Analysts have lowered their price target for Semler Scientific from $85.33 to $75.33, citing reduced revenue forecasts following cautious management guidance, weighing of recent legal settlements, and uncertainty around the company’s pivot to a bitcoin treasury strategy despite some bullish views on its potential long-term re-rating. Analyst Commentary Bullish analysts see the acquisition by Strive (ASST) as triggering potential consolidation in the corporate bitcoin treasury sector, presenting a timely opportunity despite market uncertainty around the transaction’s longer-term implications.Is Semler Scientific (NASDAQ:SMLR) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Cardiac And Digital Health Expansion Will Encounter Bitcoin Risks
Diversification into cardiac disease markets and value-based care tools positions the company for higher recurring revenues and improved long-term margins.Semler Scientific, Inc.'s (NASDAQ:SMLR) 26% Share Price Surge Not Quite Adding Up
Semler Scientific, Inc. ( NASDAQ:SMLR ) shares have had a really impressive month, gaining 26% after a shaky period...Semler Scientific: Not The Ideal Bitcoin Treasury Company
Summary Semler Scientific's pivot to a Bitcoin treasury strategy has been successful. However, competition in the Bitcoin Treasury company space is heating up, including many well funded competitors. Declining revenues and free cash flow in its healthcare business are concerning, and Bitcoin is materially outperforming the Company year to date. Read the full article on Seeking AlphaSemler Scientific, Inc.'s (NASDAQ:SMLR) 32% Price Boost Is Out Of Tune With Revenues
Semler Scientific, Inc. ( NASDAQ:SMLR ) shareholders are no doubt pleased to see that the share price has bounced 32...Here's Why We Think Semler Scientific (NASDAQ:SMLR) Might Deserve Your Attention Today
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Semler Scientific's (NASDAQ:SMLR) Profits May Not Reveal Underlying Issues
The recent earnings posted by Semler Scientific, Inc. ( NASDAQ:SMLR ) were solid, but the stock didn't move as much as...Semler Scientific, Inc. (NASDAQ:SMLR) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Unfortunately for some shareholders, the Semler Scientific, Inc. ( NASDAQ:SMLR ) share price has dived 25% in the last...Semler Scientific, Inc. (NASDAQ:SMLR) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely
Semler Scientific, Inc. ( NASDAQ:SMLR ) shares have retraced a considerable 26% in the last month, reversing a fair...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 34 | -3 | -3 | -3 | 2 |
| 12/31/2025 | 34 | 5 | -1 | -1 | 2 |
| 9/30/2025 | 37 | 48 | -27 | -27 | N/A |
| 6/30/2025 | 43 | 37 | 12 | 12 | N/A |
| 3/31/2025 | 49 | -30 | 17 | 17 | N/A |
| 12/31/2024 | 56 | 41 | 24 | 24 | N/A |
| 9/30/2024 | 59 | 16 | 22 | 21 | N/A |
| 6/30/2024 | 62 | 16 | 20 | 20 | N/A |
| 3/31/2024 | 66 | 22 | 26 | 26 | N/A |
| 12/31/2023 | 68 | 21 | 21 | 21 | N/A |
| 9/30/2023 | 67 | 20 | 17 | 19 | N/A |
| 6/30/2023 | 65 | 18 | 20 | 22 | N/A |
| 3/31/2023 | 61 | 16 | 14 | 17 | N/A |
| 12/31/2022 | 57 | 14 | 15 | 17 | N/A |
| 9/30/2022 | 54 | 13 | 16 | 17 | N/A |
| 6/30/2022 | 54 | 13 | 16 | 17 | N/A |
| 3/31/2022 | 54 | 16 | 12 | 13 | N/A |
| 12/31/2021 | 53 | 17 | 15 | 16 | N/A |
| 9/30/2021 | 54 | 21 | 19 | 20 | N/A |
| 6/30/2021 | 50 | 22 | 15 | 16 | N/A |
| 3/31/2021 | 42 | 16 | 15 | 16 | N/A |
| 12/31/2020 | 39 | 14 | 14 | 15 | N/A |
| 9/30/2020 | 36 | 11 | 12 | 13 | N/A |
| 6/30/2020 | 34 | 14 | 13 | 14 | N/A |
| 3/31/2020 | 35 | 16 | 13 | 15 | N/A |
| 12/31/2019 | 33 | 15 | 11 | 13 | N/A |
| 9/30/2019 | 30 | 14 | 10 | 11 | N/A |
| 6/30/2019 | 26 | 7 | N/A | 8 | N/A |
| 3/31/2019 | 24 | 6 | N/A | 7 | N/A |
| 12/31/2018 | 21 | 5 | N/A | 5 | N/A |
| 9/30/2018 | 20 | 4 | N/A | 3 | N/A |
| 6/30/2018 | 18 | 2 | N/A | 2 | N/A |
| 3/31/2018 | 15 | 0 | N/A | 1 | N/A |
| 12/31/2017 | 12 | -2 | N/A | 1 | N/A |
| 9/30/2017 | 11 | -2 | N/A | 0 | N/A |
| 6/30/2017 | 9 | -2 | N/A | 0 | N/A |
| 3/31/2017 | 8 | -2 | N/A | -1 | N/A |
| 12/31/2016 | 7 | -3 | N/A | -2 | N/A |
| 9/30/2016 | 8 | -7 | N/A | -4 | N/A |
| 6/30/2016 | 7 | -8 | N/A | -3 | N/A |
| 3/31/2016 | 7 | -8 | N/A | -4 | N/A |
| 12/31/2015 | 7 | -9 | N/A | -4 | N/A |
| 9/30/2015 | 5 | -5 | N/A | -4 | N/A |
| 6/30/2015 | 4 | -5 | N/A | -4 | N/A |
| 3/31/2015 | 4 | -5 | N/A | -4 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: SMLRFür die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-187.8% pro Jahr).
Ertrag vs. Markt: SMLRFür die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-187.8% pro Jahr).
Hohe Wachstumserträge: SMLRFür die nächsten 3 Jahre wird mit einem Rückgang der Erträge gerechnet.
Einnahmen vs. Markt: SMLRDie Einnahmen des Unternehmens werden in den nächsten 3 Jahren voraussichtlich zurückgehen (-5.7% pro Jahr).
Hohe Wachstumseinnahmen: SMLRDie Einnahmen des Unternehmens werden in den nächsten drei Jahren voraussichtlich zurückgehen (-5.7% pro Jahr).
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von SMLR in 3 Jahren voraussichtlich hoch sein wird
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/01/20 09:32 |
| Aktienkurs zum Tagesende | 2026/01/15 00:00 |
| Gewinne | 2025/09/30 |
| Jährliche Einnahmen | 2024/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Semler Scientific, Inc. wird von 3 Analysten beobachtet. 2 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Mark Palmer | Benchmark Company |
| Marc Wiesenberger | B. Riley Securities, Inc. |
| Brett Knoblauch | Cantor Fitzgerald & Co. |